1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,221 | 0,262 | 17:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | QLife Holding AB: Qlife provides end-year operational update on key issues | 434 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key issues.
Diabetes data
Egoo Health has achieved breakthrough... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: Qlife and Hipro sign exclusive commercial agreement covering Qlife's sale of Hipro products in EU and US markets | 97 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a first mover in clinical-grade home diagnostics, today announced that it has entered into an exclusive commercial agreement with Hipro Biotechnology Co.... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established | 202 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd.... ► Artikel lesen | |
| QLIFE Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | QLife Holding AB: Egoo Health powers AI-driven personalized diabetes management in China | 170 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") is proud to announce that its Egoo Health blood testing platform will play a central role in a groundbreaking project launched by Hipro Biotechnology Co.... ► Artikel lesen | |
| 05.12.25 | QLife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch | 110 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") a first mover in clinical-grade home diagnostics, announces publication of the clinical study for PKU children and adolescents under 18 years of age. The... ► Artikel lesen | |
| 14.11.25 | QLife Holding AB: Update on the reverse takeover process - "Red Chip" structure will not be approved by Nasdaq - other structures are pursued | 226 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or "the Company") and Hipro Biotechnology Co., Ltd. ("Hipro") are working on the planned reverse takeover, as announced in press releases on 5 June 2025 and 5 October 2025.... ► Artikel lesen | |
| 12.11.25 | Qlife Holding AB Q3 Sales Decline | 1 | RTTNews | ||
| 12.11.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q3, July - September 2025 | 122 | GlobeNewswire (Europe) | Advancing Integration & Innovation: Building a Diagnostics Powerhouse
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary... ► Artikel lesen | |
| 05.10.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended | 88 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The... ► Artikel lesen | |
| 22.09.25 | Qlife Holding AB announces the outcome of the exercise of warrants series TO 6 | 1 | Cision News | ||
| 15.09.25 | QLife Holding AB: Qlife announces additional product line and progresses two new tests into clinical trials | 144 | GlobeNewswire (Europe) | Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests-nt-proBNP and potassium-into clinical trials targeting Congestive... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q2, April to June 2025 | 229 | GlobeNewswire (Europe) | Towards a merger with a vision
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - second quarter 2025
Revenue... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: Progress update on the reverse takeover process between Qlife and Hipro | 169 | GlobeNewswire (Europe) | Gothenburg, Sweden - Qlife Holding AB ("Qlife" or the "Company") and Hipro Biotechnology Co., Ltd. ("Hipro") remain fully committed to completing the transaction announced in the Letter of Intent signed... ► Artikel lesen | |
| 21.08.25 | Qlife Holding AB increases existing credit facility and extends the maturity date | 1 | Cision News | ||
| 21.08.25 | QLIFE HOLDING AB: Qlife together with Birmingham Women's and Children's NHS Foundation Trust achieve positive results for its rare disease self-test PHE product | 2 | Cision News | ||
| 09.07.25 | QLIFE HOLDING AB: Qlife resolves to carry out a directed set-off issue of approximately SEK 2.47 million in accordance with previously announced credit facility agreement | 1 | Cision News | ||
| 05.06.25 | Qlife Holding AB receives observation status | 257 | GlobeNewswire | Today, June 5, 2025, Qlife Holding AB (the "Company") issued a press release with information that it has entered into a letter of intent for a reverse takeover of Hipro Biotechnology Co., Ltd.,... ► Artikel lesen | |
| 05.06.25 | QLife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover | 262 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co., Ltd., registration no. 91130100794182204D, ("Hipro") regarding... ► Artikel lesen | |
| 28.05.25 | QLife Holding AB: Bulletin from the annual general meeting 2025 of Qlife Holding AB | 179 | GlobeNewswire (Europe) | Qlife Holding AB held its annual general meeting on 28 May 2025. At the meeting, the following resolutions were made.
The English text is an unofficial translation. In case of any discrepancies between... ► Artikel lesen | |
| 20.05.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q1, January to March 2025 | 356 | GlobeNewswire (Europe) | Progress on all levels
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - first quarter 2025
Revenue in the... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOUNTAIN VALLEY MD | 0,007 | -37,50 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| SIEMENS HEALTHINEERS | 44,310 | -1,36 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,100 | -1,62 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| FRESENIUS | 47,770 | -2,47 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 39,360 | -1,60 % | EILMELDUNG: Carl Zeiss Meditec-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | ||
| UNITEDHEALTH | 287,95 | +2,77 % | ROUNDUP/Aktien New York: Kaum verändert am vorletzten Handelstag des Jahres | NEW YORK (dpa-AFX) - Bei den wichtigsten US-Aktienindizes hat sich am Dienstag am vorletzten Handelstag des Jahres wenig getan. Der Dow Jones Industrial sank im frühen Handel um 0,08 Prozent auf 48.423... ► Artikel lesen | |
| ECKERT & ZIEGLER | 15,050 | -1,38 % | ECKERT & ZIEGLER SE - Stabilität als strategische Basis | ||
| GERRESHEIMER | 27,820 | +0,87 % | Comeback 2026! Verzehnfachung möglich? Evotec, Gerresheimer, Desert Gold Aktie! | Auf der Suche nach einem möglichen Verzehnfacher im Gold-Sektor? Dies halten Analysten bei Desert Gold für möglich. Die jüngste PEA für das Flaggschiff-Gold-Projekt löst neue Kursfantasie aus. Damit... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 37,550 | +0,27 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| GENEDX | 136,44 | +4,91 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,020 | +1,32 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| OTTOBOCK | 65,75 | +0,77 % | IPO-Rückblick 2025: TKMS, Klarna, Ottobock und Circle im Anleger-Check | Guten Tag, liebe Leserinnen und Leser,
2025 war ein vergleichsweise starkes Jahr für Neuemissionen. Allein in der ersten Jahreshälfte wagten weltweit 539 Unternehmen den Schritt an die Börse und sammelten... ► Artikel lesen | |
| PROGYNY | 25,920 | +0,90 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 7,755 | -5,08 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook | Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year periodThird Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year periodAdjusted... ► Artikel lesen | |
| BETA BIONICS | 29,510 | -3,15 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen |
Das Unternehmen QLIFE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -13,26 % bei einem Aktienkurs von 0,242 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu QLIFE HOLDING AB finden Sie auf Wallstreet Online.